Pediatric diabetes devices and technology

Children with type 1 diabetes make more consistent use of continuous glucose monitoring if they are given the device when they initiate insulin pump therapy, rather than several months later, show the CGM TIME Trial results.

Click through to read more on this announcement

Children with type 1 diabetes who use the Tandem Control-IQ hybrid closed-loop insulin delivery system spend more time with their blood glucose levels in the target range than those using a sensor-augmented insulin pump, show findings from the iDCL trial.

Involving older children with type 1 diabetes in the decision-making process about starting continuous glucose monitoring may help to ensure that they persist with the technology, report researchers.

Continuous glucose monitoring is well accepted and reduces time in hypoglycemia among older individuals with type 1 diabetes, report researchers in JAMA.

The Omnipod Horizon closed-loop system has delivered good glucose control in its first outpatient study, the investigators report.

The Medtronic MiniMed Advanced Hybrid Closed-Loop system delivers better glycemic control than the currently approved 670G system, shows the international FLAIR trial.

Age at type 1 diabetes diagnosis does not appear to affect glycemic control and comorbidity once disease is established, but important differences occur between age groups at the time of diagnosis, US study data show.

A survey of US adolescents with type 1 diabetes has found that cost, negative attitudes towards wearing a device, and technology-related anxiety all act as obstacles preventing the use of devices in this age group.

Healthcare professionals can make false assumptions about which children with type 1 diabetes will gain most from closed-loop insulin delivery, risking children who could potentially benefit missing out, research suggests.

People with type 1 diabetes using the Tandem Control-IQ hybrid closed-loop insulin delivery system spent significantly more time within their target blood glucose range than people using a sensor-augmented insulin pump during 6 months of use in the iDCL trial.

Continuous glucose monitoring offers many benefits to the families of young children with type 1 diabetes but also a number of challenges that cannot always be overcome, show results of a qualitative analysis conducted in the USA.

Children with type 1 diabetes who are aged 6 years or younger have significantly more variability in their insulin needs than adolescents or adults, shows an analysis of closed-loop data.

Insulin pumps and multiple daily injections deliver similar glycemic control and safety profiles when allocated alongside education and support at the point of type 1 diabetes diagnosis, say researchers.

System problems and irritations lead to nearly two in five children abandoning use of closed-loop insulin delivery in a real-world setting, researchers have reported.

Responsiveness to text message reminders about blood glucose monitoring is associated with glycemic benefit among adolescents with type 1 diabetes, study findings indicate.

Giving children continuous glucose monitoring from the point of diabetes diagnosis gives their caregivers greater confidence to manage hypoglycemia and reduces their diabetes-related distress, shows a randomized trial.

Home use of day and night hybrid closed-loop insulin delivery using the Cambridge model predictive control algorithm is feasible in children aged 1–7 years with type 1 diabetes, researchers report.

The DREAM5 randomized trial has confirmed the efficacy of closed-loop insulin delivery with the MD-logic algorithm in adolescents and young adults without remote monitoring.

A randomized trial demonstrates the efficacy of closed-loop insulin delivery in a wide range of patients with poorly controlled type 1 diabetes.